High Court Rejects Mylan Appeal Of Takeda Atty Fees

Law360, New York (October 5, 2009, 6:24 PM EDT) -- The U.S. Supreme Court has declined to hear Mylan Laboratories Inc.’s appeal of a decision awarding Takeda Pharmaceutical Co. Ltd. $16.8 million in attorneys’ fees in a patent dispute over the diabetes treatment Actos.

The high court on Monday declined to review a decision in the U.S. Court of Appeals for the Federal Circuit affirming a ruling that the case should be considered exceptional in part because of the misconduct of Mylan and its subsidiary Alphapharm Pty. Ltd.

In December 2008, the appeals court found that...
To view the full article, register now.